About 5th Annual Gene Therapy Immunogenicity

Join the industry-leading forum dedicated to predicting, monitoring, and mitigating adverse immune responses to AAV gene therapies. The successful advancement of gene therapy through clinical trials depends on the development of robust, clinically validated immunoassays and biodistribution studies. These assays, combined with real-world data, are essential for overcoming efficacy and safety challenges that can impede progress and jeopardize patient safety.

Achieving a comprehensive understanding of the innate and adaptive immune responses, predictive translational models, and strategies for immunosuppression and modulation is crucial for developing safe and effective gene therapy products.

This event provides a unique opportunity to address gene therapy immunogenicity through three days of in-depth case studies, immersive workshops, and insightful panel discussions. Don't miss this chance to tackle the challenges of gene therapy immunogenicity in the present moment.